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Abstract 
Background: Despite advances in Type 2 diabetes treatment most patients will require 
insulin as their diabetes progresses. However, many patients delay insulin initiation. We 
analyzed whether psychological distress is associated with delaying insulin initiation. 
Methods: This was a 3- to 7-year follow-up of the South London Diabetes cohort study (N = 
1335). Baseline data of questionnaires regarding depressive symptoms (Patient Health 
Questionnaire), diabetes-specific distress (Problem Areas in Diabetes), and psychological 
insulin resistance (PIR; Barriers to Insulin Treatment) were used. Current medication status 
and recent HbA1c-values were collected from medical records. 
Results: There was a trend between depressive symptoms and time to becoming insulin 
requiring (HR = 1.03, 95% CI 1.00-1.06, p = .06). This trend disappeared after confounder 
adjustment. Depressive symptoms were not associated with insulin initiation delay (HR = 
1,03, 95% CI .99-1.06, p = .11). Diabetes-specific distress was associated with a shorter time 
to becoming insulin requiring (HR = 1.02, 95% CI 1.01-1.02, p < 0.001), and a shorter insulin 
initiation delay after adjustment for demographic confounders (HR = 1.01, 95% CI 1.00-1.03, 
p < 0.05). PIR was associated with a longer insulin initiation delay after confounder 
adjustment (HR = .99, 95% CI .98-1.00, p < .05). 
Conclusions: PIR was related to longer insulin initiation delay. Depressive symptoms did not 
influence insulin status. Diabetes-specific distress seemed related to a shorter time to 
becoming insulin requiring and a shorter insulin initiation delay. Further research is needed to 
examine whether addressing PIR in insulin-naïve patients could decrease insulin initiation 
delay.  
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1. Introduction 
Due to the progressive nature of Type 2 diabetes mellitus (T2DM) many patients with the 
condition will eventually need insulin therapy in order to properly manage the disease (NICE, 
2015; UKPDS, 1995). The number of patients who will require insulin initiation is rising due 
to improved life expectancy, stricter glycemic targets, and an increasing prevalence of T2DM 
(Sunaert et al., 2014). In 2014 the estimated worldwide prevalence of diabetes among adults 
was 387 million, and is expected to increase to 592 people by 2035 (International Diabetes 
Federation, 2014). According to a recent study almost one in three people will eventually 
develop T2DM (Ligthart et al., 2015). 
Inadequate diabetes management may lead to complications such as retinopathy, 
nephropathy, and cardiovascular disease (Fowler, 2008; Stratton et al., 2006). However, 
many T2DM patients delay insulin initiation for up to five years (Nichols, Koo, & Shah, 
2007; Rubino, McQuay, Gough, Kvasz, & Tennis, 2007; Ziemer et al., 2005). The aim of the 
current study was to examine whether psychological distress is related to insulin initiation 
delay in T2DM patients. 
1.1 Disease management 
T2DM is a chronic disease characterized by hyperglycemia (i.e., elevated blood glucose 
levels; Boyer, 2008). T2DM develops as a result of insulin resistance and subsequent loss of 
beta cell function (UKPDS, 1995). The management of hyperglycemia in T2DM often 
follows a stepwise strategy (NICE, 2015). At first, most T2DM patients are advised to self-
manage their diabetes by eating healthily and exercising frequently (Boyer, 2008). However, 
if these strategies do not improve glycemia, clinical guidelines suggest the addition of oral 
antidiabetic (OAD) medication (NICE, 2015). As T2DM is a progressive condition it is likely 
that glycemic control will deteriorate over time, partly due to the progressive loss of beta cell 
function (UKPDS, 1995). This will mean that pharmacological monotherapy will no longer 
be sufficient and a combination of OADs will often be needed to achieve normal glycemia 
(Fowler & Vasudeva, 2010; NICE, 2015). Newer agents such as incretin analogues are 
commonly prescribed, but these drugs are expensive and lack long-term patient safety data 
(Nathan et al., 2009). Furthermore, even these newer agents are dependent on beta cell 
function, and as there is a loss of function over time these agents will eventually no longer 
suffice to attain HbA1c target values and the majority of T2DM patients will require insulin 
therapy (NICE, 2015).  
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  Hyperglycemia increases the risk of developing diabetes complications (Fowler, 
2008; Stratton et al., 2000). Diabetes complications are commonly classified as microvascular  
(i.e., diabetic nephropathy, neuropathy, or retinopathy) and macrovascular (i.e., coronary 
artery disease, peripheral arterial disease, or stroke) complications (Fowler, 2008). In a large 
prospective study of newly diagnosed T2DM patients hyperglycemia was strongly related to 
the risk of both types of complications (Stratton et al., 2000). Each reduction of one percent 
in HbA1c was associated with a risk reduction for complications of 21 percent. The aim of 
treatment in T2DM is therefore to prevent complications by trying to achieve normal 
glycemia (Fowler, 2008). Starting insulin therapy early in the course of diabetes can improve 
glycemic control over time and reduce the risk of complications (Khunti, Vora, & Davies, 
2014; Turner, 1998; Ziemer et al., 2005). However, according to the National Diabetes Audit 
2012-2013 only 37.4 percent of T2DM patients in the United Kingdom achieved the targets 
that are recommended to reduce the risk of developing diabetes complications (HSCIC 
National Diabetes Audit, 2014). 
1.2 Psychological insulin resistance 
Despite the benefits of insulin therapy, initiation is often delayed for up to five years after 
failure of OADs (Nichols et al., 2007; Rubino et al., 2007; Ziemer et al., 2005). Cross-
sectional research suggests that at least one in four insulin-naive patients is unwilling to start 
insulin therapy if prescribed (Larkin et al., 2008; Polonsky, Fisher, Guzman, Villa-Caballero, 
& Edelman, 2005). This reluctance to start with insulin therapy is termed psychological 
insulin resistance (Polonsky et al., 2005). Patients who are unwilling to start with insulin 
therapy have reported more negative beliefs about insulin treatment (Polonsky et al., 2005). 
Common negative attitudes toward insulin therapy include a fear of needles, expected 
discomfort or pain, perceived loss of control, poor self-efficacy in managing insulin therapy, 
fear of hypoglycemia, and a feeling of a lack of fairness (Larkin et al., 2008; Makine et al., 
2009; Polonsky et al., 2005). It has been suggested that the negative appraisal of insulin is 
modifiable, as it has been demonstrated that barriers to insulin therapy increased in patients 
who remained on oral medication, whereas it decreased in patients who initiated insulin 
therapy (Hermanns, Mahr, Kulzer, Skovlund, & Haak, 2010). 
1.3 Depression and diabetes-specific-distress 
There is a high prevalence of comorbid depression in diabetes patients, with rates double that 
of the general population (Anderson, Freedland, Clouse, & Lustman, 2001). Depression is 
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associated with the onset of diabetes (Nouwen et al., 2010), poor glycemic control (Lustman 
et al., 2000), diabetes complications (Pouwer, Nefs, & Nouwen, 2013), and mortality (Fisher 
et al., 2010; Ismail, Winkley, Stahl, Chalder, & Edmonds, 2007). Furthermore, patients with a 
medical chronic disease and comorbid depression are three times more likely to be non-
adherent to treatment than non-depressed patients (DiMatteo, Lepper, & Croghan, 2000). 
Richardson and colleagues (2008) were the first to explore the relationship between 
depressive symptoms and glycemic control longitudinally. They demonstrated that depression 
was associated with poor glycemic control in T2DM. However, all participants were 
veterans, which limits the generalizability of the results as veterans tend to be older, are 
mostly men, and have more comorbidity than the general diabetes population (Miller, 
Safford, & Pogach, 2004; Richardson, Egede, Mueller, Echols, & Gebregziabher, 2008). Nefs 
and colleagues (2013) recently analyzed the association between depressive symptoms and 
insulin initiation in Dutch T2DM patients. In this study the authors did not find an association 
between depressive symptoms and time to insulin initiation. However, this finding could be 
related to some of the limitations of the study. One of the limitations was that only two 
percent of their sample was from a non-western ethnicity, whereas research suggests that 
ethnicity and culture are relevant factors with regard to insulin initiation as patients from 
ethnic minorities may have culture specific barriers to insulin therapy (Lee, Lee, & Ng, 2012; 
Polonsky et al., 2005). Furthermore, the authors only assessed depressive symptoms and did 
not assess any other psychological factors (Nefs et al., 2013). Finally, they only reported 
when people received their first insulin prescription, which can either signify an unnecessary 
delay of insulin initiation or a longer period of optimal glucose control (Nefs et al., 2013).  
Fisher and colleagues (2007) have stressed the importance of differentiating between 
depression and diabetes-specific distress. The diabetes-specific component of emotional 
distress and negative mood does not only reflect general dysphoria regarding the disease and 
the disease management, but also distress associated with regimen adherence, general health, 
comorbidities, and other diabetes-related health care, economical, social, and family 
difficulties. According to their study approximately 70 percent of patients who had high 
diabetes-specific distress did not meet the criteria for clinical depression. An important 
implication is that diabetes patients who are significantly distressed but who are not clinically 
depressed may not benefit from interventions that are derived from studies focused on 
clinical depression. Instead, it may be more meaningful and effective to address their 
diabetes-specific distress with problem solving or coping interventions focused on the 
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specific aspects of their distress, rather than interventions specifically directed at depression 
(Fisher et al., 2007). A different study (Gonzalez, Delahanty, Safren, Meigs, & Grant, 2008) 
has provided further support for the differentiation between diabetes-specific distress and 
depressive symptoms. Even though symptoms of depression and diabetes-specific distress are 
related, the results of this study provide further support that they are indeed independent 
constructs (Gonzalez et al., 2008). 
Diabetes-specific distress has been found to be associated with poor glycemic control 
(Hayashino, Okamura, Matsunaga, Tsujii, & Ishii, 2012), and poorer self-care severity 
(Mollema, Snoek, Ader, Heine, & van der Ploeg, 2001). Mixed results have been reported 
with regards to whether depressive symptoms or diabetes-specific distress is a better predictor 
of diabetes self-care. Fisher and colleagues (2007) found that diabetes-specific distress was a 
better predictor of diabetes self-care than depressive symptoms or a diagnosis of major 
depressive disorder. However, in the study by Gonzalez and colleagues (2008) depressive 
symptoms were more strongly related to diabetes-self care than diabetes-specific distress. 
Those mixed findings may be related to methodological differences (Gonzalez et al., 2008). 
A cross-sectional study demonstrated that level of depressive symptoms was the 
strongest predictor of fear of self-injection severity (Mollema et al., 2001) The association 
between depressive symptoms and negative insulin appraisal was confirmed by a more recent 
study, in which the authors also found a positive association between diabetes-specific 
distress and negative insulin appraisal that was stronger than the association with depressive 
symptoms (Makine et al., 2009). These findings suggest that in insulin-naïve T2DM patients 
diabetes-specific distress directly contributes to a more negative appraisal of insulin 
initiation. However, this association was only found in a cross-sectional study and therefore 
no assumptions about causality can be made. The longitudinal association between diabetes-
specific distress and insulin initiation has yet to be established.  
1.4 Current study 
The aim of this study was to investigate the association between psychological distress and 
insulin status. The baseline data of the South London Diabetes (SOUL-D) study were used 
and follow-up data of participants were collected. The SOUL-D study is a large prospective 
cohort study of newly diagnosed T2DM patients that started in 2007 (Winkley et al., 2013). 
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1.4.1 Insulin requiring status 
According to the guidelines of the national institute for health and care excellence (NICE) 
T2DM patients can be defined as insulin requiring when despite being on dual OAD therapy, 
a patient has suboptimal glycemic control (HbA1c ≥ 58 mmols/mol on two occasions; NICE, 
2015). It is possible that psychological distress is associated with insulin requiring status, as it 
is known that depressive symptoms and diabetes-specific distress are associated with worse 
glycemic control in diabetes patients (Hayashino et al., 2012; Lustman et al., 2000), and poor 
glycemic control could indicate a need for insulin treatment (NICE, 2015). Furthermore, as 
previous research has shown that T2DM patients with depressive symptoms appear to visit 
their physicians more often (Dzida, Karnieli, Svendsen, Sølje, & Hermanns, 2015), those 
patients might get their HbA1c-values checked more frequently at their GP, which would 
increase the chance of early detection of a need for insulin therapy. The first aim of this study 
was to determine whether depressive symptoms and diabetes-specific distress were 
prospectively associated with insulin requiring status in patients newly diagnosed with T2DM 
in South London. It was hypothesized that both depressive symptoms and diabetes-specific 
distress were independently related to a shorter time to becoming insulin requiring. This 
would indicate that psychological distress shortly after diagnosis could worsen longer-term 
diabetes outcomes.  
1.4.2 Insulin initiation  
The main aim of the study was to analyze whether psychological distress is also associated 
with a delay in insulin initiation in patients who require insulin therapy. First, we analyzed 
whether depressive symptoms were associated with insulin initiation delay. As depressive 
symptoms have been found to be associated with a negative attitude toward insulin initiation 
(Larkin et al., 2008; Makine et al., 2009; Mollema et al., 2001), as well as to patients being 
non-adherent to treatment (DiMatteo, Lepper, & Croghan, 2000), we hypothesized that 
depressive symptoms shortly after diagnosis would be associated with a longer insulin 
initiation delay in T2DM patients. The previously mentioned limitations of the study by Nefs 
and colleagues (2013) on the association between depressive symptoms and insulin initiation 
were addressed. Our sample has a diverse ethnic background as approximately 51 percent of 
the participants have a non-western ethnicity, which will increase the generalizability of the 
results. Furthermore, besides depressive symptoms we also examined other forms of 
psychological distress. Finally, as time to first insulin prescription can either signify an 
unnecessary delay of insulin initiation or a longer period of optimal glucose control (Nefs et 
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al., 2013), we determined for how long insulin had been delayed by calculating the time 
between the moment a patient became insulin requiring and the patient’s first insulin 
prescription.  
 Second, we analyzed the association between diabetes-specific distress and insulin 
initiation. Diabetes-specific distress is related to negative attitudes towards insulin initiation 
(Makine et al., 2009; Mollema et al., 2001) as well as poor diabetes self-care (Mollema et al., 
2001). Therefore we hypothesized that diabetes-specific distress would be related to a longer 
insulin initiation delay. Third, we assessed whether there was an association between PIR and 
insulin initiation. As PIR directly represents a negative attitude toward insulin initiation 
(Polonsky et al., 2005), we hypothesized that PIR would also be related to a longer insulin 
initiation delay.  
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2. Methods 
2.1 Participants 
Participants were part of an existing incident T2DM cohort (N = 1790). Eligible participants 
for this cohort were adults aged 18-75 who were recently (≤ 6 months) diagnosed with T2DM 
according to World Health Organization criteria. Patients were recruited from 90 general 
practitioner (GP) surgeries in three adjacent inner-city boroughs of South London (i.e., 
Lambeth, Southwark, and Lewisham). Participants were excluded if they met any of the 
following criteria: diagnosis of T2DM > 6 months ago, other types of diabetes, temporary 
residents, living outside of the area of the three clinical commission groups, not fluent in 
spoken English, severe mental illness (e.g., dementia, bipolar disorder, substance 
dependence, or personality disorder), advanced or terminal disease, or severe advanced 
diabetes complications (i.e., blindness, requiring dialysis, or above-knee amputation).  
2.2 Design 
The study was a prospective cohort study with a 3- to 7-year follow-up, depending on when 
participants were recruited. Table 1 depicts the number of participants who were recruited 
each year.   
 
Table 1. Number of SOUL-D Participants per Recruitment Year. 
Year of recruitment 2008 2009 2010 2011 2012 
N 94 501 509 386 294 
Years in study at time of follow-up 7 6 5 4 3 
 
2.3 Materials 
2.3.1 Baseline materials 
2.3.1.1 Baseline demographics 
Sociodemographic background variables that have been recorded include age, gender, self-
reported ethnicity, partnership status, employment status, and educational level.  
2.3.1.2 Baseline diabetes and clinical factors 
A serum blood sample was taken at baseline entry to measure HbA1c. Body mass index 
(BMI) was determined and patients were asked about the mode of diabetes onset (diabetes 
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symptoms present or absent at diagnosis). Macrovascular complications were recorded 
(history of myocardial infarction, coronary artery bypass graft, cerebrovascular accident, and 
carotid or limb re-vascularization) and presence of microvascular disease was recorded 
(neuropathy, retinopathy, and nephropathy; Winkley et al., 2013). Finally, type and dose of 
diabetes medications were reported. 
2.3.1.3 Patient Health Questionnaire (PHQ-9) 
The PHQ-9 was used to measure depressive symptoms (Kroenke, Spitzer, & Williams, 2001). 
Patients had to indicate how often they have been bother by nine different problems (e.g., 
‘feeling tired or having little energy’) during the past two weeks. The items can be answered 
on a 4-point Likert scale (0 = ‘Not at all’ to 3 = ‘Nearly every day’). Scores can range from 0 
to 27 with higher scores indicating more depressive symptoms. A score of 10 or higher 
indicates moderate to severe depressive symptoms (Kroenke & Spitzer, 2002). 
2.3.1.4 Problem Areas in Diabetes (PAID) Questionnaire.  
The PAID (Polonsky et al., 1995) questionnaire consists of 20 items that can be rated from 0 
(‘Not a problem’) to 4 (‘Serious problem’). It is a measure of negative emotions and distress 
that diabetes patients may experience while coping with their disease. Patients are asked 
which of the 20 items are currently problems for them (e.g. ‘Feelings of guilt or anxiety when 
you get off track with your diabetes management?’). Scores on all items were summed and 
multiplied by 1.25 to achieve a finals score range between 0 and 100. Scores higher than 40 
represent a high risk of emotional burnout.   
2.3.1.5 Barriers to Insulin Treatment (BIT) Questionnaire  
The BIT was used to assess patients’ psychological issues regarding insulin treatment (Petrak 
et al., 2007). We included this questionnaire as a measure of PIR.  The questionnaire consists 
of 14 statements (e.g., ‘I am afraid of the pain when injecting insulin’) and consists of five 
subscales (i.e., fear of injecting and self-testing, expectations regarding positive insulin-
related outcomes, expected hardship from insulin therapy, stigmatization by insulin 
injections, and fear of hypoglycemia). All statements could be rated from 1 (‘Totally 
disagree’) to 10 (‘Totally agree’). Higher scores indicate more psychological issues with 
insulin treatment (Petrak et al., 2007). An average score per statement of 5.57 or higher 
indicates high PIR (Boughdady et al, 2014), therefore a total score on the BIT of 78 or higher 
was used to indicate high PIR.   
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2.3.2 Follow-up materials 
The medical records of participants were accessed to collect follow-up data. HbA1c-values of 
the last three GP visits, current OAD prescriptions (type, dose, and date of first prescription), 
current insulin prescriptions (type, dose, and date of first prescription), and diabetes 
complications were reported. For patients who were on insulin therapy or who were insulin 
requiring additional HbA1c-values and data about past medication prescriptions were 
collected.  
2.4 Procedure 
The study has been granted ethics approval (King’s College Hospital Research Ethics 
Committee reference 08/H0808/1, and Lambeth, Southwark, and Lewisham Primary Care 
Trusts, reference RDLSLB 410). Participants had given informed consent for their medical 
data to be collected for up to 20 years after the baseline study. Participants who have 
withdrawn from the study in the meantime were excluded from the study. An email was sent 
to the practice managers of all GP surgeries that were included in the baseline study. If no 
reply was received within ten days, a reminder email was sent. If the practice manager did not 
respond to this second email within at least one week, we tried to contact the surgery by 
phone once. In total 55 surgeries agreed to take part in the follow-up study (Figure 1). 
 Anonymized data of the medical records of all participants were collected at the GP 
surgeries by assessing their medical records in the clinical software (EMIS or Vision) used by 
the GP and collecting the follow-up data. Participants were defined as insulin requiring if by 
three- to seven-years follow-up (depending on their year of enrollment in the study, Table 1) 
they met the NICE guidelines for intensification of therapy with insulin (i.e., despite being on 
dual OAD therapy, the patient has suboptimal glycemic control: HbA1c ≥ 7.5%, or 58 
mmols/mol on two occasions; NICE, 2015). For all patients HbA1c-values of the past three 
visits were collected. Additional HbA1c-values were collected of patients who were insulin 
requiring or had started with insulin therapy. For participants who were not registered with 
the GP anymore or who were deceased the data from their medical record were collected up 
to the point of their last consultation. 
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Figure 1. Flowchart of GP Surgeries Included in Follow-up. 
2.5 Statistical analyses 
Survival analyses were used to analyze time to becoming insulin requiring and time to insulin 
initiation. The aim of survival analyses is to model and analyze time-to-event data (Jager, van 
Dijk, Zoccali, & Dekker, 2008). With survival analyses the time until the event (i.e., 
becoming insulin requiring, or initiation of insulin therapy) occurred was analyzed. At the 
end of the follow-up period the event will however not have happened for all patients. For 
these patients the survival time will be censored, as we only know that the event did not occur 
during the follow-up period (Altman & Bland, 1998). The data of patients who were deceased 
and did not experience the event were censored on their date of death, and for patients who 
switched GP the time to event was censored at the date of their last GP visit.  
2.5.1 Kaplan-Meier method 
The most frequently used type of survival analyses is called the Kaplan-Meier method (Jager 
et al., 2008). With this method one can compare the time to event of participants in different 
groups. This method was therefore used to compare the time to becoming insulin requiring or 
time to insulin initiation of patients with low and high levels of the different types of 
psychological distress (i.e., depressive symptoms, diabetes-specific distress, and PIR). 
Survival curves were depicted and mean or median survival times were reported. As survival 
times are often highly skewed, the median is usually a better measure of central location than 
the mean. Also, censoring complicates the calculation of the mean, as all we know of 
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participants with censored data is that they have not yet experienced the event, but we do not 
know if or when they will experience the event. However, as the median represent the time 
point where the cumulative survival drops below 50 percent, the median cannot be defined 
for analyses where the cumulative survival does not drop below this percentage (Jager et al., 
2008). Therefore we included the median survival times when cumulative survival dropped 
below 50 percent, and mean survival times when this did not happen.   
To compare the survival between different groups we used the logrank test. This test 
is the most popular method of comparing the survival of groups, and takes the whole follow-
up time period into account (Bland & Altman, 2004). A disadvantage of the Kaplan-Meier 
method and logrank test is that it can only be used for categorical data. Furthermore, it is not 
possible to adjust for confounding variables with these techniques (Jager et al., 2008). 
Therefore we used Cox regression analyses to further analyze the data.  
2.5.2 Cox regression method 
For the analyses using the Cox regression method we used the discrete ordinal data of the 
questionnaire scores rather than the categorized data to increase sensitivity. One of the 
assumptions of the Cox regression model is that the hazards of different groups should be 
proportional to each other, and that the hazard ratio (HR) should be the same during the 
follow-up period (Stel, Dekker, Tripepi, Zoccali, & Jager, 2011). Even though it is unlikely 
that this assumption is ever fully satisfied, it is important to check whether there are no major 
violations as this may lead to wrong and misleading estimates of the true effect (Stel et al., 
2011). To check the assumption of proportional hazards, we first examined the Kaplan-Meier 
curves for insulin requiring status (PHQ-9 and PAID) and insulin initiation status (PHQ-9, 
PAID, and BIT). In some curves minor violations of the assumption of proportional hazards 
can be seen. For example, in Figure 6 it can be seen that that the lines of patients with low 
and high BIT scores cross. However, as we used discrete ordinal data in the Cox regression 
analyses rather than the categorized scores that are depicted in the Kaplan-Meier survival 
curves, we only used the Kaplan-Meier graphs as a first indication and the assumption of 
proportional hazards was further assessed with Schoenfeld residual plots (not depicted). The 
Schoenfeld residual tests were not significant and the plots did not reveal any major 
violations of the assumption of proportional hazards, indicating that it was appropriate to use 
Cox regression analyses. 
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2.5.3 Confounder analyses 
A negative appraisal of insulin therapy has been found to be more common in people from an 
ethnic minority (35%) than people with a white ethnicity (22%), and more common in 
women (31%) than in men (21%; Polonsky et al., 2005). Therefore we assessed whether 
ethnicity and gender were meaningful confounders in the examined associations. We also 
assessed whether age was a confounding variable, as age has previously been found to be a 
meaningful confounder in the association between depression and insulin initiation (Nefs et 
al., 2013). Variables that caused a change in the regression coefficient of at least ten percent 
were defined as meaningful confounders. We also assessed the unique association of each 
type of psychological distress on time to event by adjusting for the other types of 
psychological distress (e.g., in the analyses of the association between depressive symptoms 
and insulin initiation delay, we adjusted for diabetes-specific distress and PIR). As 
multicollinearity (high correlations among latent exogenous constructs; Grewal, Cote, & 
Baumgartner, 2004) can make it difficult to disentangle the influences of different variables 
and to obtain a good estimate of their separate effects, we first checked whether the 
correlations between the three types of psychological distress were smaller than .80 before 
including them as potential confounders.  
2.5.4 Missing data 
The multiple imputation method (Rubin, 1987) was used to handle missing data. The main 
benefit of this procedure is that all available data can still be used and no information will be 
lost (van Ginkel & Kroonenberg, 2014). With this method five unique datasets were created 
in which the missing values were imputed by random values. For the categorical analyses 
using the Kaplan-Meier method the data of the first imputed dataset are reported as no pooled 
results were provided. However, we did analyze all five datasets, and there were no major 
differences between the results of the five datasets. For the Cox regression analyses the 
pooled results of the five imputed datasets are reported.  
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3. Results 
3.1 Participants 
The present sample includes all SOUL-D participants of whom follow-up data were collected 
(N = 1335). No data were collected of the 455 SOUL-D participants who were registered 
with the 35 GP surgeries that did not take part in the follow-up. Participants in the follow-up 
did not differ significantly from participants who were not included in the follow-up on any 
of the background variables, except for medication status (Table 2). Participants who were 
not included in the follow-up were more likely to use diabetic medication at baseline (58.2%, 
χ2 = 4.292, p < .05). Specifically, they were more likely to use OADs at baseline (58.2%, χ2 = 
4.285, p < .05).  
 
Table 2. Baseline Demographics.  
 N missing M SD % (valid) 
Demographics     
   Age 0 55.82 10.96  
   Female sex 0   45.4 
   Non-western ethnicity 12   50.7 
   Employed 1   47.5 
   Low education level     
Medical history      
   Diabetes duration (years) 3 .39 .17  
   HbA1C 92 53.25 16.17  
   Macrovascular disease 20   8.5 
   Microvascular disease 256   33.8 
Diabetes medication     
   Taking diabetes medication 19   52.6* 
   OAD 21   52.6* 
   Insulin 8   3.5 
Questionnaires     
   PHQ-9 39 4.40 5.23  
   PAID 135 10.86 15.03  
   BIT 141 64.61 20.59  
* p < .05, compared to the 455 participants who were not included in the follow-up.  
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PHQ-9, PAID, and BIT scores were all significantly related to each other (Table 2). All 
regression coefficients had scores that were below .80, which indicates that there was no 
multicollinearity. 
 
Table 2. Regression Coefficients.  
 PHQ-9 PAID BIT 
PHQ-9  .52** .09* 
PAID .52**  .24** 
BIT .09* .24**  
* p < .01, ** p < .001 
 
There were no follow-up data available for 21 patients. 237 patients switched GP and 42 
patients deceased during the follow-up period (Table 2).  
 
Table 2. Attrition.  
  Time in days 
Cause N (%)  M SD 
Switched GP 237 (17.8) 879.41 536.68 
Deceased 42 (3.1) 1149.24 608.95 
Unknown 21 (1.6)   
 
Overall patients’ HbA1c-values of their last visit were relatively high (M = 57.47, SD = 
41.15, n = 1281). Most patients were being treated with OADs (70.5%). During a mean 
follow-up period of 1540.26 ± 558.85 days (range 29 – 2532), 86 (6.7%) patients had started 
insulin therapy, which was often combined with OADs (77.9%; Table 3). 30 patients who 
started with insulin therapy had delayed initiation (34.9%). 123 patients (10.3%) were insulin 
requiring but had not started with insulin therapy.  
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Table 3. Medication Status at Follow-up.  
Type of medication  n % (valid) 
OAD 907 70.5 
  1 623 67.0 
  2  258 27.7 
  3 48 5.2 
  4 1 .1 
Insulin 86 6.7 
  Combined with OAD 67 77.9 
  Previously on OAD 6 15.1 
  No OAD  13 7.0 
 
3.3 Insulin requiring status 
Data of all participants (N = 1335) were used to examine the association between 
psychological distress and time to becoming insulin requiring.  
3.3.1 Kaplan-Meier 
The mean time to becoming insulin requiring is depicted in Table 4. No difference was found 
in time to becoming insulin requiring between patients with low and high depressive 
symptoms, χ2 (1) = .97, p = .33 (Figure 2). Diabetes-specific distress was related to time to 
becoming insulin requiring χ2 (1) = 4.98, p < .05. In Figure 3 it can be seen that patients with 
high diabetes-specific distress had a shorter time to becoming insulin requiring than patients 
with low distress. Table 4 depicts the mean scores of time to becoming insulin requiring.  
 
Table 4. Time to Becoming Insulin Requiring in days. 
 M SD 95% CI 
   Lower Upper 
PHQ-9     
   Low (<10) 2282.43 20.10 2243.03 2321.82 
   High (≥10) 2190.45 51.03 2090.44 2290.47 
PAID     
   Low (<41) 2286.61 18.98 2249.41 2323.80 
   High (≥41) 2108.21 96.04 1919.98 2296.44 
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     Figure 2. Survival Curves PHQ-9  
     (Insulin Requiring Status). 
     Figure 3. Survival Curves PAID  
     (Insulin Requiring Status).  
3.3.2 Cox regression  
The association between PHQ-9 score and time showed a non-significant positive trend (B = 
.028, HR = 1.03, 95% CI 1.00-1.06, p = .06). Sex and age were found to be meaningful 
confounders (Table 5). Adjusting for sex led to a significant association, but after further 
adjustment for age the effect remained non-significant. 
 
Table 5. Change in Regression Coefficient for PHQ-9 after Adjustment for Potential 
Confounders (Insulin Requiring Status). 
 
Potential confounder 
PHQ-9 
HR (95% CI) p  B Change in B (%) 
Age 1.02 (.99-1.05) .33 .015 -46.4 
Sex 1.03 (1.00-1.06) .04 .031 10.7 
Ethnicity 1.03 (1.00-1.06) .07 .026 7.1 
Base model* 1.02 (.99-1.05) .23 .018 -35.7 
Base model* + PAID 1.01 (.98-1.04) .60 .009 -50 
* Adjusted for age and sex. 
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There was a significant positive association between PAID score and time to becoming 
insulin requiring (B = .015, HR = 1.02, 95% CI 1.01-1.02, p < .001), indicating that patients 
with higher diabetes-specific distress had a shorter time to becoming insulin requiring. Age 
and ethnicity were meaningful confounders (Table 6) and adjusting for these factors made the 
association non-significant. PHQ-9 was a meaningful confounder of the base model. 
 
Table 6. Change in Regression Coefficient for PAID after Adjustment for Potential 
Confounders (Insulin Requiring Status). 
 
Potential confounder 
PAID 
HR (95% CI) p  B Change in B (%) 
Age 1.01 (1.00-1.02) .18 .007 -53.3 
Sex 1.02 (1.01-1.03) .00 .016 6.7 
Ethnicity 1.01 (1.00-1.02) .00 .013 -13.3 
Base model* 1.01 (1.00-1.02) .19 .006 -60.0 
Base model* + PHQ-9 1.01 (.99-1.02) .35 .005 -16.7 
* Adjusted for age and ethnicity. 
3.3 Insulin initiation status 
Data of patients who were either insulin requiring or on insulin therapy were used for the 
analyses (n = 219 after multiple imputation).  
3.2.1 Kaplan-Meier 
The median of the time to insulin initiation is depicted in Table 7. There was no significant 
difference in time to insulin initiation between patients with low and high depressive 
symptoms, χ2 (1) = .81, p = .37 (Figure 4), or patients with low and high diabetes-specific 
distress diabetes-specific distress, χ2 (1) = .05, p = .82 (Figure 5). There was also no 
difference between patients with low and high levels of PIR, χ2 (1) = .01, p = .91 (Figure 6). 
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Table 7. Time to Insulin Initiation (in Days). 
   95% CI 
 Median SE Lower Upper 
PHQ-9     
   Low (<10) 1385.00 286.53 823.53 1946.60 
   High (≥10) 721.00 189.91 348.78 1093.22 
PAID     
   Low (<41) 1385.00 319.09 759.59 2010.41 
   High (≥41) 1322.00 575.98 193.08 2450.9 
BIT     
   Low (<78) 1567.00 500.42 586.18 2547.82 
   High (≥78) 1322.00 380.27 576.66 2067.34 
 
  
     Figure 4. Survival Curves PHQ-9  
     (Insulin Initiation Status). 
     Figure 5. Survival Curves PAID  
     (Insulin Initiation Status). 
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     Figure 6. Survival Curves BIT  
     (Insulin Initiation Status). 
3.2.2 Cox Regression 
There was no association between PHQ-9 score and time to insulin initiation (B = .028, HR = 
1.03, 95% CI .99-1.06, p = .11). Only PAID was a meaningful confounder (Table 8). The 
association remained non-significant after adjusting for this confounder.  
 
Table 8. Change in Regression Coefficient for PHQ-9 after Adjustment for Potential 
Confounders (Insulin Initiation). 
 PHQ-9 
 HR (95% CI) p B Change in B (%) 
Age 1.03 (.99-1.06) .11 .027 -3.6 
Sex 1.03 (.99-1.06) .11 .028 0 
Ethnicity 1.03 (.99-1.06) .11 .027 -3.6 
PAID 1.02 (.98-1.07) .29 -.022 -21.4 
BIT 1.03 (1.00-1.06) .10 .028 0 
 
There was no association between PAID score and time to insulin initiation (B = .007, HR = 
1.01, 95% CI 1.00-1.02, p = .19). Age and ethnicity were meaningful confounders (Table 9) 
and adjusting for these factors led to a significant positive association, indicating that higher 
levels of diabetes-specific distress were related to a shorter delay in insulin initiation when 
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adjusted for those variables. Both PHQ-9 and BIT scores were meaningful confounders, and 
correcting the base model for these confounders made the association non-significant.  
 
Table 9. Change in Regression Coefficient for PAID after Adjustment for Potential 
Confounders (Insulin Initiation). 
 PAID 
Potential confounder HR (95% CI) p   B Change in B (%) 
Age 1.01 (1.00-1.02) .23  .007 -12.5 
Sex 1.01 (1.01-1.02) .19  .008 0 
Ethnicity 1.02 (1.01-1.03) .00  .019 50 
Base model*  1.01 (1.00-1.03) .02  .013 62.5 
Base model* + PHQ-9 1.01 (1.00-1.02) .18  .009 -30.7 
Base model* + BIT 1.01 (1.00-1.02) .13  .010 -23.1 
* Adjusted for age and ethnicity. 
 
There was a non-signification trend between BIT score and time to insulin initiation (B = - 
.010, HR = .99, 95% CI .98-1.00, p = .07). Ethnicity was a meaningful confounder (Table 
10). Correcting for this variable led to a negative trend that was almost significant.  PAID 
score was a meaningful confounder of the base model, and adjusting for this led to a 
significant association between BIT score and time to insulin initiation (Table 10), indicating 
that higher BIT scores were related to a longer time to insulin initiation. 
 
Table 10. Change in Regression Coefficient for BIT after Adjustment for Potential 
Confounders (Insulin Initiation). 
 BIT 
Potential confounder HR (95% CI) p   B Change in B (%) 
Age .99 (.98-1.00) .06  -.010 0 
Sex .99 (.98-1.00) .07  -.010 0 
Ethnicity .99 (.97-1.00) .05  -.011 -10 
Base model* + PHQ-9 .99 (.98-1.00) .05  -.011 0 
Base model* + PAID .99 (.98-1.00) .03  -.013 -18.2 
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4. Discussion 
In the current study we assessed the association between psychological distress and insulin 
initiation in T2DM patients. Specifically, we looked at the association between psychological 
distress (depressive symptoms, and diabetes-specific distress) and insulin requiring status, 
and the association between psychological distress (depressive symptoms, diabetes-specific 
distress, and PIR) and insulin initiation delay in patients who were insulin requiring.  
4.1 Insulin requiring status 
A positive trend between depressive symptoms an insulin requiring status was found. This 
would indicate that patients who scored high on depressive symptoms shorty after diagnosis, 
would require insulin sooner than patients who scored lower. However, this trend was not 
significant and after adjusting for confounders the trend disappeared.  
 As previous research has shown that diabetes-specific distress is related to a worse 
glycemic control (Hayashino et al., 2012) we expected that diabetes-specific distress would 
be related to a shorter time to requiring insulin therapy. Our results provide support for this 
hypothesis, as the analyses revealed that diabetes-specific distress was associated with a 
shorter time to becoming insulin requiring. The finding that diabetes-specific distress, but not 
depressive symptoms, is related to a shorter time to becoming insulin requiring (indicating 
less good glycemic control) is in line with the findings by Fisher and colleagues (2007) who 
reported that diabetes-specific distress was a better predictor of diabetes self-care than 
depressive symptoms. However, adjusting for meaningful confounders made the association 
non-significant.  
4.2 Insulin initiation delay  
Depressive symptoms were not related to insulin initiation delay. Diabetes-specific distress 
was related to a shorter insulin initiation delay, but only when corrected for age and ethnicity. 
This is in contrast with our hypothesis, as we expected that diabetes-specific distress would 
be related to a longer delay. However, both depressive symptoms and PIR were found to be 
meaningful confounders and correcting for those confounders made the association non-
significant.  
  The analyses on diabetes-specific distress and insulin initiation revealed a trend that is 
in contrast with our hypotheses. As previous research showed that diabetes patients with 
depression have worse glycemic control than patients without depression (Lustman et al., 
2000), we expected that patients who scored high on psychological distress would show a 
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shorter time to becoming insulin requiring as being insulin requiring can indicate worse 
control. Further research is needed to explore this association. If future studies would indeed 
confirm that diabetes-specific distress is related to a shorter time to becoming insulin 
requiring, a possible explanation would be that patients with high psychological distress may 
visit their healthcare professionals more frequently, as previous research has indicated that 
T2DM patients with depressive symptoms appear to visit their physicians more often (Dzida, 
Karnieli, Svendsen, Sølje, & Hermanns, 2015). It is possible that this is also true for diabetes-
specific distress. If patients get their HbA1c-values checked more frequently at their GP, it is 
likely that the topic of insulin initiation is mentioned more frequently by the GP, which could 
explain why those patients would start insulin therapy sooner.   
Finally, we analyzed the association between PIR and insulin initiation delay. As 
predicted, PIR was associated with a longer delay in insulin initiation after adjusting for 
meaningful confounders. This indicates that patients with higher levels of PIR at baseline 
delayed insulin initiation for a longer time period. This shows that negative feelings regarding 
insulin treatment could predict a delay in insulin initiation. This result suggests that it might 
be beneficial to address negative insulin beliefs in patients with newly diagnosed T2DM. 
Further research should assess whether an intervention focused on decreasing negative 
insulin beliefs in these patients could indeed decrease insulin initiation delay.  
4.3 Limitations and suggestions for further research 
The current study has several limitations. First, the percentage of patients who were insulin 
requiring or on insulin was relatively low. As previous studies have found that insulin 
initiation is often delayed for up to five years (Nichols et al., 2007; Rubino et al., 2007; 
Ziemer et al., 2005) our follow-up period of three- to seven-years might have been too short. 
As the percentage of patients in our cohort who require insulin or who have initiated insulin 
therapy will increase with time, we suggest a second follow-up of this cohort after 
approximately five years to get a more reliable indication of the association between 
psychological distress and insulin initiation.  
  Second, the use of OAD at baseline was significantly higher in the group of 
participants who were not included in the follow-up. As these patients were using more 
diabetes medication at baseline, it is possible that the proportion of patients who are insulin 
requiring or who have started insulin therapy is higher in the group of patients who were not 
included. We were unable to include those patients in the follow-up as the GP surgeries did 
not respond to the request for the follow-up. For a future follow-up it might therefore be 
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helpful to apply for funding, so a monetary reward can be offered to the GP surgeries as an 
incentive to participate in the follow-up. 
Third, the percentage of patients who switched from GP was high (17.8%). For these 
patients only the data were collected until their last visit at their initial GP surgery. For future 
follow-up studies it is suggested to try to contact these patients using the contact details that 
were provided at baseline, and collect their follow-up data at their new GP surgery.  
 Fourth, we only used patients’ baseline data as a measure of psychological distress. 
However, it is likely that patients’ levels of psychological distress have changed over time 
(e.g., some patients may have developed more depressive symptoms or diabetes specific-
distress during the course of their diabetes).  For most patients the questionnaires were 
repeated one and two years after the baseline study. By including those data in a future 
follow-up the mean scores of psychological distress in the first two years after diagnosis 
could be determined. 
Fifth, collecting data from patients’ medical records gives a reliable indication of the 
status of their diabetes control, but it does not indicate if or when the GP has mentioned 
insulin therapy. According to the NICE (2015) guidelines a GP should do this after the 
HbA1c-value has been too high on two occasions, even though the patient is already on at 
least two types of OAD. However, we are not certain whether all GPs have actually followed 
these guidelines and suggested insulin therapy as soon as a patient became insulin requiring.  
  Finally, we only analyzed the total scores on the questionnaires. With regard to 
depressive symptoms, the heterogeneity of subtypes and severity of depression (APA, 2000) 
could mean that there is an association between depressive symptoms and insulin initiation, 
but only when certain characteristics of depression are present (e.g., low self-esteem, Nefs et 
al., 2013). With regards to PIR, the BIT questionnaire consists of five subscales which 
represent different aspects of negative beliefs about insulin therapy (Petrak et al., 2007). 
Further analyses of the different subscales could result in a better understanding of 
association between the different aspects of PIR and insulin initiation.  
4.4 Conclusions 
In the current study we looked at the association between psychological distress, and insulin 
requiring status and insulin initiation delay. Depressive symptoms were not related to either 
insulin requiring status or insulin initiation delay. Some support was found for the hypothesis 
that diabetes-specific distress was related to a shorter time to becoming insulin requiring. In 
contrast to our hypothesis, diabetes-specific distress was also found to be associated with a 
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shorter insulin initiation delay. Further research is needed to get a better understanding of this 
association and to explore whether the frequency of GP visits may be a mediator in this 
association. PIR was associated with a longer insulin initiation delay, which indicates that it 
might be helpful to develop an intervention focused on reducing negative beliefs about 
insulin therapy for T2DM patients who score high on PIR, as to prevent or decrease insulin 
initiation delay. Exploring why a person is unwilling to start with insulin therapy can help to 
address patients’ individual needs. For example, it could be helpful to teach patients at an 
early stage of their disease that T2DM is progressive and insulin will often be required. This 
might decrease feelings of personal failure when insulin therapy is suggested (Larkin et al., 
2008). Further research is needed to get a better understanding of the exact associations 
between different types of psychological distress and insulin initiation delay.   
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